Trials / Completed
CompletedNCT00749138
Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Bader, Ted, M.D. · Individual
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.
Detailed description
Six different dosages of tamoxifen will be given for 14 days with safety and viral loads being measured.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tamoxifen | giving drug tamoxifen |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-05-01
- Completion
- 2009-10-01
- First posted
- 2008-09-09
- Last updated
- 2010-03-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00749138. Inclusion in this directory is not an endorsement.